Janus Henderson Group’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-6,939,503
| Closed | -$501M | – | 2455 |
|
|
2025
Q4 | $501M | Sell |
6,939,503
-7,583,412
| -52% | -$490M | 0.22% | 106 |
|
|
2025
Q3 | $633M | Buy |
14,522,915
+3,745,598
| +35% | +$151M | 0.29% | 70 |
|
|
2025
Q2 | $306M | Sell |
10,777,317
-649,379
| -6% | -$19.4M | 0.15% | 147 |
|
|
2025
Q1 | $361M | Buy |
11,426,696
+4,373,686
| +62% | +$136M | 0.2% | 123 |
|
|
2024
Q4 | $205M | Buy |
7,053,010
+2,156,844
| +44% | +$90.1M | 0.1% | 190 |
|
|
2024
Q3 | $225M | Buy |
4,896,166
+1,239,323
| +34% | +$53.8M | 0.12% | 176 |
|
|
2024
Q2 | $149M | Buy |
3,656,843
+2,414,010
| +194% | +$69.3M | 0.08% | 210 |
|
|
2024
Q1 | $31.7M | Buy |
1,242,833
+1,216,730
| +4,661% | +$19.1M | 0.02% | 477 |
|
|
2023
Q4 | $236K | Sell |
26,103
-38
| -0.1% | -$254 | ﹤0.01% | 2367 |
|
|
2023
Q3 | $167K | Buy |
26,141
+21
| +0.1% | +$181 | ﹤0.01% | 2424 |
|
|
2023
Q2 | $289K | Sell |
26,120
-36
| -0.1% | -$452 | ﹤0.01% | 2266 |
|
|
2023
Q1 | $401K | Buy |
+26,156
| New | +$575K | ﹤0.01% | 2141 |
|
|
2020
Q4 | – | Sell |
-180,446
| Closed | -$5.08M | – | 1425 |
|
|
2020
Q3 | $5.08M | Sell |
180,446
-143,157
| -44% | -$4.14M | ﹤0.01% | 921 |
|
|
2020
Q2 | $9.14M | Buy |
+323,603
| New | +$9.33M | 0.01% | 827 |
|
Other funds holding RNAM
Janus Henderson Group's RNAM Position: Q1 2026 in Review
Janus Henderson Group sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 6,939,503 shares — an estimated $501M sold.
Janus Henderson Group first reported a position in RNAM in Q2 2020 and held it in 14 quarters. The position peaked at $633M in Q3 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Janus Henderson Group reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Janus Henderson Group sold 6,939,503 Avidity Biosciences shares in Q1 2026, an estimated $501M.
- Janus Henderson Group first reported a position in Avidity Biosciences in Q2 2020 and held it in 14 quarters.
- Janus Henderson Group's Avidity Biosciences position peaked at $633M in Q3 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.